ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
AstraZeneca's Fasenra offers severe asthma patients 2 years of benefits
May 21, 2019AstraZeneca’s Fasenra has been stealing share from GlaxoSmithKline’s Nucala in severe asthma, and competition is even fiercer with Sanofi’s Dupixent approval. -
G-BA confirms Teva's Cinqaero gives minor additional benefit in severe asthma
July 11, 2017The German Federal Joint Committee (G-BA) has determined that Teva Pharmaceuticals Europe's Cinqaero (reslizumab) provides minor additional benefit in certain asthma cases.
Pharma Sources Insight January 2025
